Stephen Oh

Congrats to all awardees + special shoutout to my dear friend, collaborator & sage adviser Jorge Di Paola truly deserving of the ASH Mentor Award! 🥳🙌👏 @washumedicine.bsky.social

Proud to roll with this crew! 🤩 Celebrating our graduating students Varun, Lowell, and Tim! 🥳

Congrats Katherine! 🎉

We further unveil a novel therapeutic approach utilizing a first-in-class RSK inhibitor, PMD-026, that suppressed disease burden across syngeneic and PDX leukemia mouse models spanning the spectrum of driver and disease-modifying mutations.

Combining ATAC-Seq, CUT&Tag, RNA-seq, and CyTOF, we demonstrate that targeting of RSK1 suppresses NFκB activation and diminishes pro-inflammatory mediators including TNF associated with MPN disease severity and transformation.

Here we establish a comprehensive atlas across MPNs and secondary AML including RNA-sequencing of 158 primary samples encompassing CD34+ HPSCs and CD14+ monocytes. Supported by mass cytometry (CyTOF) profiling, we reveal aberrant PI3K/AKT/mTOR signaling and NFκB-mediated hyper-inflammation.

Drug in clinical trials for breast cancer could also treat some blood cancers | WashU Medicine Researchers are working with industry toward a clinical trial for blood cancer patients

Delighted to share our latest study now online @naturecomms.bsky.social! Thanks to 1st author Tim Kong + multiple Oh Lab members & collaborators for their contributions! #hemesky @washumedicine.bsky.social @sitemancenter.bsky.social
medicine.washu.edu/news/drug-in...
www.nature.com/articles/s41...

Postdoc candidates check out this exciting opportunity! 🤩 #HemeSky

🎉 Happy Holidays from #OhLab #TeamMPN! 🎉 #familypic #holidayparty #BooCatClub #speakeasyafterparty

Was too busy with 🥳🍷🎉to take many pics but had so much fun at our WashU Hematology reception Friday evening especially co-hosting with great friend and collaborator Jorge Di Paola! #ASH24 @ash-hematology.bsky.social

Nice back 2 back talks & worlds colliding with new WashU faculty Helen Ajufo presenting her studies wifh Raajit Rampal and Jeff Zwicker + former WashU IM resident Joan How presenting GASTRO-MPN a collaborative effort including our faculty Kristen Sanfilippo! #ASH24 @ash-hematology.bsky.social

🤩 Wow wow wow #ASH24 attendees have 2x opportunities today to catch Molly Brakhane presenting her work today!

🏃🏃‍♀️🏃‍♂️Jog/run/sprint (don’t walk) to the poster walk at 11:15am featuring Molly’s poster.

And come to the poster session this evening (#1169)! 😁

@ash-hematology.bsky.social

Excited for this workshop this afternoon and grateful to the organizers Christina Glytsou, Panos Ntziachristos, & Dan Starczynowski for the opportunity to speak in the session alongside @gritsmanlab.bsky.social & Marek Mraz! #ASH24 #hemesky @ash-hematology.bsky.social
ash.confex.com/ash/2024/web...

Ready to board the WashU bus to #ASH24! @ash-hematology.bsky.social #hemesky

And check out my talk on Friday afternoon at the Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies where I will be highlighting work from superstar MSTP student Tim Kong!
ash.confex.com/ash/2024/web...

Come to Fan's oral presentation during the MPN session on Monday afternoon!
ash.confex.com/ash/2024/web...

Check out Molly's presentation during the poster walk on Saturday morning & at the evening poster session!
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...

Super proud of Oh Lab members Molly Brakhane & Fan He presenting at #ASH24! 🤩

Both are recipients of @ash-hematology.bsky.social abstract achievement awards! 🥳

#mpnsm #ASHkudos

Everyone headed to #ASH24 - if you’re looking for your favorite scientists in hematopoiesis to follow on here, we have you covered 👇🏼

#Publixsub FTW > Moffit or Coronado pizza #amirite

Very exciting Beth, congrats to your team and looking forward to these presentations!

very cool paper by @mpndoc.bsky.social et al looking at RSK1 as a therapeutic target in FLT3-ITD AML!

www.nature.com/articles/s41...

Stay tuned for our companion manuscript which we anticipate sharing soon 😀. Finally, check out my talk on this work at the #ASH24 Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies!
@ash-hematology.bsky.social
ash.confex.com/ash/2024/web...

Also grateful to long-time collaborator Grant Challen as well as Sandi Dunn and Phoenix Molecular Designs for working closely with us on this effort. Excited to move this concept into the clinic in the near future!

Finally, we demonstrated that the first-in-class RSK inhibitor PMD-026 ameliorated leukemic disease burden across multiple FLT3-mutant animal models. These findings illustrate an unconventional and promising therapeutic strategy targeting FLT3-ITD leukemia.

We further found elevated expression of RPS6KA1 and USP1 to be associated with poor prognosis, revealing novel biomarkers that may be predictive of AML patient survival and therapeutic response to FLT3-ITD inhibitors.

We uncovered a unique bi-directional mechanism by which RSK1 regulates FLT3-ITD activity and protein stability via deubiqutinase USP1.

RSK1 dependency in FLT3-ITD acute myeloid leukemia - Blood Cancer Journal Blood Cancer Journal - RSK1 dependency in FLT3-ITD acute myeloid leukemia

On this Thanksgiving Day 🦃 I am especially grateful to WashU MSTP student Tim Kong and additional Oh Lab members whose hard work and commitment led to our new manuscript delineating RSK1 as a core dependency in FLT3-ITD AML, now online in Blood Cancer Journal!
#hemesky
www.nature.com/articles/s41...

Will be there with bells on 😀 #ASH24

I had a wonderful visit to Wash U to deliver the Evan Sadler lecture last month! Thanks for the invitation. It was great to hear about the fantastic science there. The faculty and trainees are awesome! #hemesky @ttagggttagggttaggg.bsky.social @mpndoc.bsky.social @frederickdenorme.bsky.social et al